Immuno-oncology company TCR2 Therapeutics to go public with $80 million IPO

Trending News 🌥️

Tcr2 Therapeutics Stock Fair Value – TCR2 ($NASDAQ:TCRR) Therapeutics is an immuno-oncology company that plans to go public with an $80 million IPO. The company is focused on developing T-cell therapies to treat cancer.

TCR2 has raised $125 million to advance its two T-cell therapies, which are in clinical trials. The company plans to use the proceeds from the IPO to fund clinical trials, commercialization efforts, and general corporate purposes.

Stock Price

The company has been the subject of negative media exposure recently, and on Thursday, its stock opened at $1.8 and closed at $1.8, down 2.2% from the previous closing price. Despite the recent negativity, the company remains optimistic about its future prospects.

VI Analysis – Tcr2 Therapeutics Stock Fair Value Calculator

TCR2 THERAPEUTICS is a clinical-stage immuno-oncology company developing novel T cell therapies for the treatment of solid tumors and blood cancers. The company’s proprietary technology involves the use of T cells that are genetically modified to express a novel T cell receptor that can recognize and kill cancer cells. The company’s fundamentals reflect its long term potential.

The fair value of TCR2 THERAPEUTICS share is around $10.4, calculated by VI Line. The company is currently trading at $1.8, which represents a discount of 83%.

Summary

Investing in TCR2 Therapeutics may be a risky proposition at this time as the company is set to go public with an $80 million IPO and media exposure has been mostly negative. However, the company is working on cutting-edge immuno-oncology treatments that could prove to be very successful in the future. If you believe in the potential of the company’s technology, then investing now could prove to be profitable.